A2-Iso5-2DC18 是一种二氢咪唑连接脂类，是一种强效的 mRNA 传递载体。A2-Iso5-2DC18 能够用于包括 B16F10 黑色素瘤在内的抗肿瘤的研究。
| 生物活性 | A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma.[1]. |
体内研究
(In Vivo) | A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model[1].
A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15 μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-? secretion in B16F10 mouse melanoma model[1].
| Animal Model: | A14/Cre mRNA mouse model (female B6 mice)[1] | | Dosage: | Loaded with Cre-recombinase mRNA LNPs (mCre); 0.1 mg/kg and 0.5 mg/kg | | Administration: | Subcutaneous injection; 3 weeks | | Result: | Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice. |
| Animal Model: | Ovalbumin (OVA)-expressing B16F10 mouse melanoma model[1] | | Dosage: | Loaded with OVA mRNA (mOVA) vaccine; 15 μg mOVA per mouse | | Administration: | Subcutaneous injection; once per week for the first two weeks; 3 weeks continuous observation | | Result: | Significantly decreased tumor volume of B16-OVA melanoma and improved overall survival in mice.
Increased the number of systemic and tumor-infiltrating antigen-specific T cells dramatically (20–30-fold). |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com